


*April 2007*



drug trend report

# 2006 Drug Trend Report



**EXPRESS SCRIPTS®**



**Lead Authors**

Julayna Meyer, MBA, RPh  
Andy Parker, MBA  
Aimee Tharaldson, PharmD  
Chris Peterson, PharmD

**Contributors**

Andy Behm, PharmD  
Jonah Houts  
Jane Miller  
Brenda Motheral, PhD, MBA, RPh  
Jann Rigell, RPh  
Brian Seiz, PharmD  
Ed Weisbart, MD, CPE

**Editor**

Ruth Martinez, RPh

The authors and editor would like to acknowledge the valuable support of the analysts, reviewers, researchers and sponsors who contributed to the *2006 Drug Trend Report*. We greatly appreciate the time and expertise of numerous individuals throughout the Express Scripts organization — particularly members of the Clinical, Decision Support, Marketing & Corporate Communications, Modeling & Analysis, Product Management, and Research teams.

## Preface

Dear Reader:

2006 truly was an historic year. With this 11th edition of the Express Scripts *Drug Trend Report*, we recap the year's opportunities and challenges in making the use of prescription drugs safer and more affordable.

Last year, more than \$13 billion in 2005 brand-drug spend went generic, with the blockbuster, cholesterol-lowering drug Zocor® (simvastatin) topping the list. Never before had there been such a tremendous opportunity to save money without a negative impact on health outcomes.


Clients and patients saved more than \$125 million following the introduction of simvastatin alone, using a combination of financial incentives, targeted information, customized assistance and timely messaging. This patient-education model, coupled with heightened PBM and plan-sponsor collaboration, will certainly be important going forward. It is the "power of us" in action.

Also, during 2006, trend for expensive, but critically important specialty drugs rose 20.9%, largely due to higher costs per prescription, increased utilization and the introduction of new medications.

Increasingly, plan sponsors are choosing specialty-drug formularies to manage costs, successfully applying principles from traditional drug-formulary development. Even more importantly, they are using specialty clinical programs to improve patient outcomes through enhanced overall care.

Thank you for your interest in this report, and in our mission of making the use of prescription drugs safer and more affordable.

Sincerely,

A handwritten signature in black ink, appearing to read 'G. Paz', with a long horizontal line extending from the end of the signature.

George Paz  
Chairman & Chief Executive Officer